NCT03564379View on ClinicalTrials.gov

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

August 13, 2018

Study Completion Date

August 13, 2018

Conditions
Healthy
Interventions
DRUG

JNJ-42165279

25 mg JNJ-42165279 tablet will be administered orally.

DRUG

Placebo

Matching placebo tablet will be administered orally.

Trial Locations (1)

90630

WCCT Global, LLC, Cypress

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03564379 - A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants | Biotech Hunter | Biotech Hunter